CorpWatch : Gilead Sciences Under Investigation for Over-Charging for Hepatitis C Pill

July 21, 2014 2:23 PM

12 0

CorpWatch : Gilead Sciences Under Investigation for Over-Charging for Hepatitis C Pill

Gilead Sciences of San Francisco is under investigation by the U.S. Senate Finance Committee for charging $84,000 for a 12 week course of a new drug to treat hepatitis C. Gilead sells the exact same course for $900 in poor countries like Egypt and India.

Sovaldi - the brand name for sofosbuvir - was approved last December by the U.S. Food and Drug Administration, to treat hepatitis C, a viral infection that can cause fever, fatigue, cirrhosis and deadly liver cancer. Some 150 million people around the world are estimated to be at risk, often many ye...

Read more

To category page

Loading...